Lung Cancer

Tecentriq plus Chemotherapy Approved as First Therapy for Metastatic Lung Cancer without EGFR or ALK Mutations

Late in 2019, the FDA approved the combination of immunotherapy plus chemotherapy as the first-line treatment for patients with non–small-cell lung cancer that does not harbor EGFR or ALK mutations, which are often associated with lung cancer.
December 2019 Vol 5 No 6

In December 2019, the FDA approved Tecentriq (atezolizumab; from Genentech), a PD-1 inhibitor, in combination with Abraxane (paclitaxel protein-bound) and carboplatin chemotherapy, as first-line therapy for adults with metastatic non-squamous non–small-cell lung cancer (NSCLC) that does not harbor EGFR or ALK genomic mutations.

Tecentriq has been previously approved by the FDA for several cancers, including NSCLC with EGFR or ALK mutations, and bladder and breast cancers.

This new approval was based on results of a clinical trial showing improved survival and time without disease progression with Tecentriq in patients with NSCLC without EGFR or ALK mutations versus chemotherapy alone. The average survival was 18.6 months with Tecentriq versus 13.9 months with chemotherapy.

The most common side effects with atezolizumab plus chemotherapy were fatigue, nausea, alopecia, constipation, diarrhea, and decreased appetite.

Recommended For You
COVID-19 (Coronavirus)Lung CancerWeb Exclusives
Updated Joint Statement on Coronavirus (COVID-19) from Lung Cancer Groups
LUNGevity and 4 other lung cancer organizations have provided information on the new coronavirus for people with lung cancer and other patients with cancer. This update also provides reliable sources of information for patients.
COVID-19 (Coronavirus)Lung CancerWeb Exclusives
COVID-19 FAQs for People with Lung Cancer
LUNGevity answers some frequently asked questions about patients with lung cancer and survivors and the coronavirus illness.
COVID-19 (Coronavirus)Lung Cancer
COVID-19 Conversation: Introduction
By Zosia Piotrowska, MD, MHS
In this series of videos from LUNGevity, oncologist Zosia Piotrowska, MD, MHS, Massachusetts General Hospital, Boston, addresses many of the questions and concerns raised in regard to coronavirus COVID-19 and patients with lung cancer.
COVID-19 (Coronavirus)Lung Cancer
COVID-19 Conversation: Part 1: About Coronavirus – COVID-19
By Zosia Piotrowska, MD, MHS
Oncologist Dr. Zosia Piotrowska addresses some specific questions about the impact of COVID-19. She discusses dealing with anxiety, symptoms, who is most at risk for the illness, how it is spread, how to avoid getting the illness, and the available treatments.
Last modified: March 12, 2020

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.